Profuse oral secretions after propafenone administration in neonates.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 20659741.
- Also identified by DOI 10.1016/j.jpeds.2010.06.028.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Propafenone, an antiarrhythmic drug that is effective for treating supraventricular tachycardias, can induce well-known proarrhythmic and systemic adverse effects. We describe a previously unreported adverse effect in 3 newborns: oral propafenone-induced profuse oral secretions and respiratory distress of sufficient severity to necessitate discontinuation of propafenone.
Medical subject headings
- Anti-Arrhythmia Agents
- Propafenone
- Respiratory Distress Syndrome, Newborn